onMRI™
AI-driven MRI analysis system converting subjective interpretation into reproducible quantitative biomarkers (cartilage/meniscus segmentation, T2 mapping, low-field MRI compatibility).
Founder and Strategic Lead. Innovate UK KTP; patent pending.
Quick facts
At a glance
- Professor Lee's role
- Founder and Strategic Lead
- Focus
- Cartilage and meniscus segmentation, T2 mapping, low-field MRI compatibility
- Grants
- Innovate UK Knowledge Transfer Partnership
- IP
- Patent pending
- Status
- Active
What it is
onMRI is the AI-driven MRI analysis platform that converts subjective MRI interpretation into reproducible quantitative biomarkers. Cartilage and meniscus segmentation, T2 mapping and compatibility with low-field MRI systems are the headline outputs. Innovate UK KTP, patent pending.
Why it matters
MRI is the most powerful musculoskeletal imaging modality in routine use. Its read remains substantially subjective, which makes consistent decision-making harder and makes published comparisons across centres less reliable. onMRI puts an explainable, reproducible quantitative layer on top of the MRI read.